Opnurasib

Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1) . Opnurasib shows antitumor activity[1][2].

Product Specifications

CAS Number

[2653994-08-0]

Product Name Alternative

JDQ-443; NVP-JDQ443

UNSPSC

12352005

Target

PERK; Ras

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/opnurasib.html

Purity

98.20

Solubility

DMSO : 80 mg/mL (ultrasonic)

Smiles

O=C(C=C)N1CC2(C1)CC(N3N=C(C4=CC=C5C(C=NN5C)=C4)[C@]([C@]6=C(Cl)C(C)=CC7=C6C=NN7)=C3C)C2

Molecular Formula

C29H28ClN7O

Molecular Weight

526.03

References & Citations

[1]LIU BO, et al. PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS. Patent WO2021120890A1.|[2][2] Weiss A, Lorthiois E, Barys L, et al. Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent and Selective, Covalent Oral Inhibitor of KRASG12C. Cancer Discov. 2022; candisc.0158.2022.